These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
335 related items for PubMed ID: 26817948
1. Sacubitril Is Selectively Activated by Carboxylesterase 1 (CES1) in the Liver and the Activation Is Affected by CES1 Genetic Variation. Shi J, Wang X, Nguyen J, Wu AH, Bleske BE, Zhu HJ. Drug Metab Dispos; 2016 Apr; 44(4):554-9. PubMed ID: 26817948 [Abstract] [Full Text] [Related]
2. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. Shi J, Wang X, Nguyen JH, Bleske BE, Liang Y, Liu L, Zhu HJ. Biochem Pharmacol; 2016 Nov 01; 119():76-84. PubMed ID: 27614009 [Abstract] [Full Text] [Related]
3. A Comprehensive Functional Assessment of Carboxylesterase 1 Nonsynonymous Polymorphisms. Wang X, Rida N, Shi J, Wu AH, Bleske BE, Zhu HJ. Drug Metab Dispos; 2017 Nov 01; 45(11):1149-1155. PubMed ID: 28838926 [Abstract] [Full Text] [Related]
4. CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors. Wang X, Wang G, Shi J, Aa J, Comas R, Liang Y, Zhu HJ. Pharmacogenomics J; 2016 Jun 01; 16(3):220-30. PubMed ID: 26076923 [Abstract] [Full Text] [Related]
5. Impact of carboxylesterase 1 genetic polymorphism on trandolapril activation in human liver and the pharmacokinetics and pharmacodynamics in healthy volunteers. Wang X, Her L, Xiao J, Shi J, Wu AH, Bleske BE, Zhu HJ. Clin Transl Sci; 2021 Jul 01; 14(4):1380-1389. PubMed ID: 33660934 [Abstract] [Full Text] [Related]
6. Contributions of Cathepsin A and Carboxylesterase 1 to the Hydrolysis of Tenofovir Alafenamide in the Human Liver, and the Effect of CES1 Genetic Variation on Tenofovir Alafenamide Hydrolysis. Li J, Shi J, Xiao J, Tran L, Wang X, Zhu HJ. Drug Metab Dispos; 2022 Mar 01; 50(3):243-248. PubMed ID: 34933885 [Abstract] [Full Text] [Related]
9. Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators. Her L, Zhu HJ. Drug Metab Dispos; 2020 Mar 01; 48(3):230-244. PubMed ID: 31871135 [Abstract] [Full Text] [Related]
10. Effect of CES1 genetic variation on enalapril steady-state pharmacokinetics and pharmacodynamics in healthy subjects. Her LH, Wang X, Shi J, Choi HJ, Jung SM, Smith LS, Wu AH, Bleske BE, Zhu HJ. Br J Clin Pharmacol; 2021 Dec 01; 87(12):4691-4700. PubMed ID: 33963573 [Abstract] [Full Text] [Related]
15. Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor. Ayalasomayajula S, Langenickel T, Pal P, Boggarapu S, Sunkara G. Clin Pharmacokinet; 2017 Dec 01; 56(12):1461-1478. PubMed ID: 28417439 [Abstract] [Full Text] [Related]
16. Different hydrolases involved in bioactivation of prodrug-type angiotensin receptor blockers: carboxymethylenebutenolidase and carboxylesterase 1. Ishizuka T, Yoshigae Y, Murayama N, Izumi T. Drug Metab Dispos; 2013 Nov 01; 41(11):1888-95. PubMed ID: 23946449 [Abstract] [Full Text] [Related]
17. Genetic variation in human carboxylesterase CES1 confers resistance to hepatic steatosis. Lian J, Bahitham W, Panigrahi R, Nelson R, Li L, Watts R, Thiesen A, Lemieux MJ, Lehner R. Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Jul 01; 1863(7):688-699. PubMed ID: 29631096 [Abstract] [Full Text] [Related]
20. Examination of the carboxylesterase phenotype in human liver. Ross MK, Borazjani A, Wang R, Crow JA, Xie S. Arch Biochem Biophys; 2012 Jun 01; 522(1):44-56. PubMed ID: 22525521 [Abstract] [Full Text] [Related] Page: [Next] [New Search]